Investigation of NS3 protease resistance-associated variants and phenotypes for the prediction of treatment response to HCV triple therapy

PLoS ONE

Volumn 11, Issue 6, 2016, Pages

  Dietz, Julia ^a   Rupp, Daniel ^b   Susser, Simone ^a   Vermehren, Johannes ^a   Peiffer, Kai Henrik ^a   Filmann, Natalie ^c   Bon, Dimitra ^c   Kuntzen, Thomas ^d   Mauss, Stefan ^e   Grammatikos, Georgios ^a   Perner, Dany ^a   Berkowski, Caterina ^a   Herrmann, Eva ^c   Zeuzem, Stefan ^a   Bartenschlager, Ralf ^b   Sarrazin, Christoph ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c GOETHE UNIVERSITY   (Germany)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e Zentrum fur HIV und Hepatogastroenterologie   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE; BOCEPREVIR; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GENOMIC DNA; INTERFERON; INTERFERON LAMBDA4; NONSTRUCTURAL PROTEIN 3; PROTEINASE; TELAPREVIR; UNCLASSIFIED DRUG; VIRUS RNA; ANTIVIRUS AGENT; NS3 PROTEIN, HEPATITIS C VIRUS; VIRAL PROTEIN;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATIONAL STUDY; FEMALE; GENE; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HOST; HUMAN; IFNL4 GENE; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PHENOTYPE; PREDICTION; PREDICTIVE VALUE; REPLICON; RESISTANCE ASSOCIATED VARIANT; SENSITIVITY AND SPECIFICITY; SEX; SINGLE NUCLEOTIDE POLYMORPHISM; SUSTAINED VIROLOGIC RESPONSE; TREATMENT RESPONSE; VIROLOGIC FAILURE; ANTAGONISTS AND INHIBITORS; ANTIVIRAL RESISTANCE; CLINICAL TRIAL; DRUG EFFECTS; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; MIDDLE AGED; MULTICENTER STUDY; TREATMENT OUTCOME; VIROLOGY;

ADULT; AGED; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; TREATMENT OUTCOME; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84976272244     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0156731     Document Type: Article

References (40)

1. Sarrazin C, Hezode C, Zeuzem S, Pawlotsky JM. Antiviral strategies in hepatitis C virus infection. Journal of hepatology. 2012; 56 Suppl 1:S88-100. doi: 10.1016/S0168-8278(12)60010-5 PMID: 22300469.
2. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. The New England journal of medicine. 2011; 364(25):2405-16. doi: 10.1056/NEJMoa1012912 PMID: 21696307.
3. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. The New England journal of medicine. 2011; 364(13):1195-206. doi: 10.1056/NEJMoa1010494 PMID: 21449783; PubMed Central PMCID: PMC3766849.
4. Barnard RJ, Howe JA, Ogert RA, Zeuzem S, Poordad F, Gordon SC, et al. Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies. Virology. 2013; 444(1-2):329-36. doi: 10.1016/j.virol.2013.06.029 PMID: 23876458.
5. Kieffer TL, De Meyer S, Bartels DJ, Sullivan JC, Zhang EZ, Tigges A, et al. Hepatitis C viral evolution in genotype 1 treatment-naive and treatment-experienced patients receiving telaprevir-based therapy in clinical trials. PloS one. 2012; 7(4):e34372. doi: 10.1371/journal.pone.0034372 PMID: 22511937; PubMed Central PMCID: PMC3325239.
6. De Meyer S, Dierynck I, Ghys A, Beumont M, Daems B, Van Baelen B, et al. Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: results from the REALIZE trial. Hepatology. 2012; 56(6):2106-15. doi: 10.1002/hep.25962 PMID: 22806681.
7. Sullivan JC, De Meyer S, Bartels DJ, Dierynck I, Zhang EZ, Spanks J, et al. Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2013; 57(2):221-9. doi: 10.1093/cid/cit226 PMID: 23575197.
8. Howe AY, Long J, Nickle D, Barnard R, Thompson S, Howe J, et al. Long-term follow-up of patients receiving boceprevir for treatment of chronic hepatitis C. Antiviral research. 2015; 113:71-8. doi: 10.1016/j.antiviral.2014.10.010 PMID: 25446895.
9. Susser S, Vermehren J, Forestier N, Welker MW, Grigorian N, Fuller C, et al. Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir. Journal of clinical virology: the official publication of the Pan American Society for Clinical Virology. 2011; 52(4):321-7. doi: 10.1016/j.jcv.2011.08.015 PMID: 21924672.
10. Sarrazin C. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. Journal of hepatology. 2015. doi: 10.1016/j.jhep.2015.09.011 PMID: 26409317.
11. Sarrazin C, Berg T, Cornberg M, Dollinger M, Ferenci P, Hinrichsen H, et al. [Expert opinion on boceprevir- and telaprevir-based triple therapies of chronic hepatitis C]. Z Gastroenterol. 2012; 50(1):57-72. doi: 10.1055/s-0031-1282015 PMID: 22222799.
12. Dietz J, Schelhorn SE, Fitting D, Mihm U, Susser S, Welker MW, et al. Deep sequencing reveals mutagenic effects of ribavirin during monotherapy of hepatitis C virus genotype 1-infected patients. Journal of virology. 2013; 87(11):6172-81. doi: 10.1128/JVI.02778-12 PMID: 23536652; PubMed Central PMCID: PMC3648094.
13. Lim SR, Qin X, Susser S, Nicholas JB, Lange C, Herrmann E, et al. Virologic escape during danoprevir (ITMN-191/RG7227) monotherapy is hepatitis C virus subtype dependent and associated with R155K substitution. Antimicrobial agents and chemotherapy. 2012; 56(1):271-9. doi: 10.1128/AAC.05636-11 PMID: 22064535; PubMed Central PMCID: PMC3256012.
14. Dietz J, Susser S, Berkowski C, Perner D, Zeuzem S, Sarrazin C. Consideration of Viral Resistance for Optimization of Direct Antiviral Therapy of Hepatitis C Virus Genotype 1-Infected Patients. PloS one. 2015; 10(8):e0134395. doi: 10.1371/journal.pone.0134395 PMID: 26317755; PubMed Central PMCID: PMCPMC4552686.
15. Hall TA. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucleic Acids Symposium. 1999; 41:95-8.
16. Bartels DJ, Sullivan JC, Zhang EZ, Tigges AM, Dorrian JL, De Meyer S, et al. Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment. Journal of virology. 2013; 87(3):1544-53. doi: 10.1128/JVI.02294-12 PMID: 23152524; PubMed Central PMCID: PMC3554180.
17. Friebe P, Lohmann V, Krieger N, Bartenschlager R. Sequences in the 5′ nontranslated region of hepatitis C virus required for RNA replication. Journal of virology. 2001; 75(24):12047-57. doi: 10.1128/JVI.75.24.12047-12057.2001 PMID: 11711595; PubMed Central PMCID: PMCPMC116100.
18. Qi X, Bae A, Liu S, Yang H, Sun SC, Harris J, et al. Development of a replicon-based phenotypic assay for assessing the drug susceptibilities of HCV NS3 protease genes from clinical isolates. Antiviral research. 2009; 81(2):166-73. doi: 10.1016/j.antiviral.2008.11.002 PMID: 19063924.
19. Esser-Nobis K, Romero-Brey I, Ganten TM, Gouttenoire J, Harak C, Klein R, et al. Analysis of hepatitis C virus resistance to silibinin in vitro and in vivo points to a novel mechanism involving nonstructural protein 4B. Hepatology. 2013; 57(3):953-63. doi: 10.1002/hep.26260 PMID: 23322644; PubMed Central PMCID: PMCPMC3593759.
20. Friebe P, Boudet J, Simorre JP, Bartenschlager R. Kissing-loop interaction in the 3′ end of the hepatitis C virus genome essential for RNA replication. Journal of virology. 2005; 79(1):380-92. doi: 10.1128/JVI.79.1.380-392.2005 PMID: 15596831; PubMed Central PMCID: PMCPMC538730.
21. van den Hoff MJ, Christoffels VM, Labruyere WT, Moorman AF, Lamers WH. Electrotransfection with "intracellular" buffer. Methods Mol Biol. 1995; 48:185-97. doi: 10.1385/0-89603-304-X:185 PMID: 8528391.
22. Susser S, Herrmann E, Lange C, Hamdi N, Muller T, Berg T, et al. Predictive value of interferon-lambda gene polymorphisms for treatment response in chronic hepatitis C. PloS one. 2014; 9(11):e112592. doi: 10.1371/journal.pone.0112592 PMID: 25393304; PubMed Central PMCID: PMCPMC4231027.
23. Peiffer KH, Sommer L, Susser S, Vermehren J, Herrmann E, Doring M, et al. Interferon lambda 4 genotypes and resistance-associated variants in patients infected with hepatitis C virus genotypes 1 and 3. Hepatology. 2016; 63(1):63-73. doi: 10.1002/hep.28255 PMID: 26406534.
24. Jacobson IM, Pawlotsky JM, Afdhal NH, Dusheiko GM, Forns X, Jensen DM, et al. A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C. Journal of viral hepatitis. 2012; 19 Suppl 2:1-26. doi: 10.1111/j.1365-2893.2012.01590.x PMID: 22404758.
25. Kau A, Vermehren J, Sarrazin C. Treatment predictors of a sustained virologic response in hepatitis B and C. Journal of hepatology. 2008; 49(4):634-51. doi: 10.1016/j.jhep.2008.07.013 PMID: 18715665.
26. Grammatikos G, Lange C, Susser S, Schwendy S, Dikopoulos N, Buggisch P, et al. Vitamin D levels vary during antiviral treatment but are unable to predict treatment outcome in HCV genotype 1 infected patients. PloS one. 2014; 9(2):e87974. doi: 10.1371/journal.pone.0087974 PMID: 24516573; PubMed Central PMCID: PMCPMC3917831.
27. Darling JM, Aerssens J, Fanning G, McHutchison JG, Goldstein DB, Thompson AJ, et al. Quantitation of pretreatment serum interferon-gamma-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response. Hepatology. 2011; 53(1):14-22. doi: 10.1002/hep.24056 PMID: 21254158; PubMed Central PMCID: PMCPMC3083026.
28. Howe JA, Long J, Black S, Chase R, McMonagle P, Curry S, et al. Clinical Implications of Detectable Baseline Hepatitis C Virus-Genotype 1 NS3/4A-Protease Variants on the Efficacy of Boceprevir Combined With Peginterferon/Ribavirin. Open Forum Infectious Diseases. 2014; 1(2):1-7.
29. Vermehren J, Sarrazin C. The role of resistance in HCV treatment. Best practice & research Clinical gastroenterology. 2012; 26(4):487-503. doi: 10.1016/j.bpg.2012.09.011 PMID: 23199507.
30. Schneider MD, Sarrazin C. Antiviral therapy of hepatitis C in 2014: do we need resistance testing? Antiviral research. 2014; 105:64-71. doi: 10.1016/j.antiviral.2014.02.011 PMID: 24583028.
31. Kuntzen T, Timm J, Berical A, Lennon N, Berlin AM, Young SK, et al. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. Hepatology. 2008; 48(6):1769-78. doi: 10.1002/hep.22549 PMID: 19026009; PubMed Central PMCID: PMC2645896.
32. Hoffmann L, Faffe DS, Lima JFC, Capitanio TA, Cabral BCA, Ürményi TP, et al. No correspondence betweeen resistance mutations iin the HCV-NS3 protease at baseline and early telaprevir-based therapy. BBA Clinical. 2015; 3:146-51. doi: 10.1016/j.bbacli.2015.01.004 PMID: 26674563
33. Dierynck I, Thys K, Ghys A, Sullivan JC, Kieffer TL, Aerssens J, et al. Deep-sequencing analysis of the gene encoding the hepatitis C virus nonstructural 3-4A protease confirms a low prevalence of telaprevir-resistant variants at baseline and the end of the REALIZE study. The Journal of infectious diseases. 2014; 210(12):1871-80. doi: 10.1093/infdis/jiu340 PMID: 24943725.
34. Sarrazin C, Dvory-Sobol H, Svarovskaia ES, Doehle B, McCarville JF, Pang PS, et al. Baseline and Post-baseline Resistance Analyses of Phase 2/3 Studies of Ledipasvir/Sofosbuvir ± RBV Hepatology. 2014; 60(Supplement S1):1128A.
35. Stross C, Shimakami T, Haselow K, Ahmad MQ, Zeuzem S, Lange CM, et al. Natural HCV variants with increased replicative fitness due to NS3 helicase mutations in the C-terminal helix alpha18. Sci Rep. 2016; 6:19526. doi: 10.1038/srep19526 PMID: 26787124; PubMed Central PMCID: PMCPMC4726148.
36. Albillos A, Lario M, Alvarez-Mon M. Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance. Journal of hepatology. 2014; 61(6):1385-96. doi: 10.1016/j.jhep.2014.08.010 PMID: 25135860.
37. Sarrazin C, Dvory-Sobol H, Svarovskaia ES, Doehle B, Martin R, Zeuzem S, et al. The prevalence and the effect of HCV NS5A resistance associated variants in subjects with compensated cirrhosis treated with ledipasvir/sofosbuvvir +/- RBV. Journal of hepatology. 2015; 62(1):S620.
38. Grebely J, Page K, Sacks-Davis R, van der Loeff MS, Rice TM, Bruneau J, et al. The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology. 2014; 59(1):109-20. doi: 10.1002/hep.26639 PMID: 23908124; PubMed Central PMCID: PMCPMC3972017.
39. Al Ashgar H, Helmy A, Khan MQ, Al Kahtani K, Al Quaiz M, Rezeig M, et al. Predictors of sustained virological response to a 48-week course of pegylated interferon alfa-2a and ribavirin in patients infected with hepatitis C virus genotype 4. Ann Saudi Med. 2009; 29(1):4-14. PMID: 19139619; PubMed Central PMCID: PMCPMC2813618.
40. Bressler BL, Guindi M, Tomlinson G, Heathcote J. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology. 2003; 38(3):639-44. doi: 10.1053/jhep.2003.50350 PMID: 12939590.